{"id":13874,"date":"2025-10-09T13:02:00","date_gmt":"2025-10-09T11:02:00","guid":{"rendered":"https:\/\/iph-multisite.berta-bewegt.ch\/?p=13874"},"modified":"2026-02-26T16:20:51","modified_gmt":"2026-02-26T15:20:51","slug":"acces-aux-nouveaux-medicaments-un-defia-portee-de-main","status":"publish","type":"post","link":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/","title":{"rendered":"Acc\u00e8s aux nouveaux m\u00e9dicaments, un d\u00e9fi\u00e0 port\u00e9e de main"},"content":{"rendered":"\n<p><em>Dans une interview accord\u00e9e \u00e0 L&rsquo;AGEFI, Ren\u00e9 Buholzer s&rsquo;est exprim\u00e9 sur l&rsquo;acc\u00e8s aux nouveaux m\u00e9dicaments. Vous pouvez lire l&rsquo;article original <a href=\"https:\/\/agefi.com\/actualites\/opinions\/la-securite-dapprovisionnement-en-nouveaux-medicaments-un-defi-a-portee-de-main\"><u>ici<\/u><\/a><\/em>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-\"><\/h2>\n\n\n\n<p><\/p>\n\n\n\n<p>Ces derni\u00e8res ann\u00e9es, la s\u00e9curit\u00e9 d\u2019approvisionnement en nouveaux m\u00e9dicaments s\u2019est nettement d\u00e9grad\u00e9e en Suisse. L\u2019\u00e9tude WAIT montre qu\u2019en comparaison europ\u00e9enne de l\u2019acc\u00e8s aux traitements innovants, la Suisse n\u2019est plus qu\u2019\u00e0 la 7<sup>e<\/sup> place, juste devant la Bulgarie. Tandis que deux fois plus de nouveaux m\u00e9dicaments sont disponibles en Allemagne, tout juste la moiti\u00e9 des m\u00e9dicaments autoris\u00e9s par l\u2019autorit\u00e9 europ\u00e9enne du m\u00e9dicament arrivent sur le march\u00e9 suisse.<\/p>\n\n\n\n<p>La raison en est un syst\u00e8me obsol\u00e8te de formation des prix: des substances qui existent depuis des dizaines d\u2019ann\u00e9es servent de traitements de comparaison, tandis qu\u2019on ne tient pas compte du b\u00e9n\u00e9fice qu\u2019apportent les traitements modernes, par exemple moins de journ\u00e9es d\u2019h\u00f4pital ou d\u2019op\u00e9rations superflues. De ce fait, les patientes et patients de Suisse attendent des m\u00e9dicaments auxquels la population d\u2019autres pays a acc\u00e8s depuis longtemps.<\/p>\n\n\n\n<p><strong>\u00ab&nbsp;Corrig\u00e9s de la parit\u00e9 de pouvoir d&rsquo;achat, les prix suisses sont inf\u00e9rieurs \u00e0 la moyenne europ\u00e9enne&nbsp;\u00bb<\/strong><\/p>\n\n\n\n<p>On oublie souvent de prendre en compte que, en comparaison internationale, la Suisse est relativement \u00e9conome dans le domaine des m\u00e9dicaments. Corrig\u00e9s de la parit\u00e9 de pouvoir d&rsquo;achat, les prix suisses sont inf\u00e9rieurs \u00e0 la moyenne europ\u00e9enne. Les d\u00e9penses pour les traitements innovants ne sont qu\u2019\u00e0 un quart du niveau des \u00c9tats-Unis. Concr\u00e8tement, le Suisse moyen d\u00e9pense 37\u00a0francs par mois pour des m\u00e9dicaments innovants, trois fois moins que pour l\u2019alcool et le tabac. Sur ce montant, 27\u00a0francs vont aux fabricants, 1\u00a0franc \u00e0 l\u2019\u00c9tat ainsi qu\u2019aux fournisseurs de prestations et environ 8\u00a0francs au commerce. \u00c0 l\u2019exception du financement uniforme des soins EFAS, les grands leviers d\u2019\u00e9conomies dans le syst\u00e8me de sant\u00e9, qui ne mettraient en danger, ni la qualit\u00e9, ni l\u2019approvisionnement, n\u2019ont pas \u00e9t\u00e9 abord\u00e9s.<\/p>\n\n\n\n<p>Le conflit commercial avec les \u00c9tats-Unis aggrave la situation, car ces derniers envisagent de coupler les prix des m\u00e9dicaments aux prix europ\u00e9ens les plus bas (\u00abprix de la nation la plus favoris\u00e9e\u00bb). Les entreprises seraient ainsi incit\u00e9es \u00e0 retarder la mise sur le march\u00e9 dans les pays aux prix bas, de mani\u00e8re \u00e0 \u00e9viter des effets n\u00e9gatifs sur le march\u00e9 am\u00e9ricain. Les patientes et patients suisses en souffriraient \u00e9galement, car les traitements n\u2019arriveraient que plus tard, voire pas du tout. Les nouvelles taxes douani\u00e8res montrent qu\u2019il ne s\u2019agissait pas de menaces en l\u2019air des \u00c9tats-Unis, et cela a des cons\u00e9quences pour l\u2019approvisionnement, mais aussi pour l\u2019exportation, les imp\u00f4ts et l\u2019emploi.<\/p>\n\n\n\n<p>Pour assurer la place de recherche et la s\u00e9curit\u00e9 d\u2019approvisionnement, nous avons besoin de trois choses: premi\u00e8rement, l\u2019arr\u00eat de projets de r\u00e9glementation qui causent des co\u00fbts suppl\u00e9mentaires \u00e9lev\u00e9s et sapent l\u2019attractivit\u00e9 du petit march\u00e9 suisse. Deuxi\u00e8mement, une strat\u00e9gie coordonn\u00e9e des sciences de la vie qui apporte les conditions cadres capables d\u2019assurer l\u2019avenir de la contribution \u00e9conomique de la branche \u00e0 l\u2019approvisionnement, la recherche, l\u2019emploi et la prosp\u00e9rit\u00e9. Troisi\u00e8mement, la modernisation attendue depuis trop longtemps du syst\u00e8me de formation des prix, de mani\u00e8re \u00e0 ce que le progr\u00e8s b\u00e9n\u00e9ficie aussi aux patient-e-s de notre pays.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dans une interview accord\u00e9e \u00e0 L&rsquo;AGEFI, Ren\u00e9 Buholzer s&rsquo;est exprim\u00e9 sur l&rsquo;acc\u00e8s aux nouveaux m\u00e9dicaments. Vous pouvez lire l&rsquo;article original ici. Ces derni\u00e8res ann\u00e9es, la s\u00e9curit\u00e9 d\u2019approvisionnement en nouveaux m\u00e9dicaments s\u2019est nettement d\u00e9grad\u00e9e en Suisse. L\u2019\u00e9tude WAIT montre qu\u2019en comparaison europ\u00e9enne de l\u2019acc\u00e8s aux traitements innovants, la Suisse n\u2019est plus qu\u2019\u00e0 la 7e place, juste [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":13875,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"tags":[],"class_list":["post-13874","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Acc\u00e8s aux nouveaux m\u00e9dicaments, un d\u00e9fi\u00e0 port\u00e9e de main - Interpharma<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acc\u00e8s aux nouveaux m\u00e9dicaments, un d\u00e9fi\u00e0 port\u00e9e de main - Interpharma\" \/>\n<meta property=\"og:description\" content=\"Dans une interview accord\u00e9e \u00e0 L&rsquo;AGEFI, Ren\u00e9 Buholzer s&rsquo;est exprim\u00e9 sur l&rsquo;acc\u00e8s aux nouveaux m\u00e9dicaments. Vous pouvez lire l&rsquo;article original ici. Ces derni\u00e8res ann\u00e9es, la s\u00e9curit\u00e9 d\u2019approvisionnement en nouveaux m\u00e9dicaments s\u2019est nettement d\u00e9grad\u00e9e en Suisse. L\u2019\u00e9tude WAIT montre qu\u2019en comparaison europ\u00e9enne de l\u2019acc\u00e8s aux traitements innovants, la Suisse n\u2019est plus qu\u2019\u00e0 la 7e place, juste [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/\" \/>\n<meta property=\"og:site_name\" content=\"Interpharma\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-09T11:02:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-26T15:20:51+00:00\" \/>\n<meta name=\"author\" content=\"berta_admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"berta_admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/\"},\"author\":{\"name\":\"berta_admin\",\"@id\":\"https:\/\/iph-multisite.berta-bewegt.ch\/#\/schema\/person\/749c3574947ecc016332eb58d91e45a3\"},\"headline\":\"Acc\u00e8s aux nouveaux m\u00e9dicaments, un d\u00e9fi\u00e0 port\u00e9e de main\",\"datePublished\":\"2025-10-09T11:02:00+00:00\",\"dateModified\":\"2026-02-26T15:20:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/\"},\"wordCount\":609,\"image\":{\"@id\":\"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/iph-multisite.berta-bewegt.ch\/wp-content\/uploads\/2026\/02\/width1920quality75formatauto.avif\",\"inLanguage\":\"fr-FR\",\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\/\/iph-multisite.berta-bewegt.ch\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/\",\"url\":\"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/\",\"name\":\"Acc\u00e8s aux nouveaux m\u00e9dicaments, un d\u00e9fi\u00e0 port\u00e9e de main - Interpharma\",\"isPartOf\":{\"@id\":\"https:\/\/iph-multisite.berta-bewegt.ch\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/iph-multisite.berta-bewegt.ch\/wp-content\/uploads\/2026\/02\/width1920quality75formatauto.avif\",\"datePublished\":\"2025-10-09T11:02:00+00:00\",\"dateModified\":\"2026-02-26T15:20:51+00:00\",\"author\":{\"@id\":\"https:\/\/iph-multisite.berta-bewegt.ch\/#\/schema\/person\/749c3574947ecc016332eb58d91e45a3\"},\"breadcrumb\":{\"@id\":\"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/#primaryimage\",\"url\":\"https:\/\/iph-multisite.berta-bewegt.ch\/wp-content\/uploads\/2026\/02\/width1920quality75formatauto.avif\",\"contentUrl\":\"https:\/\/iph-multisite.berta-bewegt.ch\/wp-content\/uploads\/2026\/02\/width1920quality75formatauto.avif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acc\u00e8s aux nouveaux m\u00e9dicaments, un d\u00e9fi\u00e0 port\u00e9e de main\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/iph-multisite.berta-bewegt.ch\/#website\",\"url\":\"https:\/\/iph-multisite.berta-bewegt.ch\/\",\"name\":\"Interpharma\",\"description\":\"Verband der forschenden Pharmazeutischen Firmen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/iph-multisite.berta-bewegt.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/iph-multisite.berta-bewegt.ch\/#\/schema\/person\/749c3574947ecc016332eb58d91e45a3\",\"name\":\"berta_admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"caption\":\"berta_admin\"},\"sameAs\":[\"https:\/\/iph-multisite.berta-bewegt.ch\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Acc\u00e8s aux nouveaux m\u00e9dicaments, un d\u00e9fi\u00e0 port\u00e9e de main - Interpharma","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Acc\u00e8s aux nouveaux m\u00e9dicaments, un d\u00e9fi\u00e0 port\u00e9e de main - Interpharma","og_description":"Dans une interview accord\u00e9e \u00e0 L&rsquo;AGEFI, Ren\u00e9 Buholzer s&rsquo;est exprim\u00e9 sur l&rsquo;acc\u00e8s aux nouveaux m\u00e9dicaments. Vous pouvez lire l&rsquo;article original ici. Ces derni\u00e8res ann\u00e9es, la s\u00e9curit\u00e9 d\u2019approvisionnement en nouveaux m\u00e9dicaments s\u2019est nettement d\u00e9grad\u00e9e en Suisse. L\u2019\u00e9tude WAIT montre qu\u2019en comparaison europ\u00e9enne de l\u2019acc\u00e8s aux traitements innovants, la Suisse n\u2019est plus qu\u2019\u00e0 la 7e place, juste [&hellip;]","og_url":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/","og_site_name":"Interpharma","article_published_time":"2025-10-09T11:02:00+00:00","article_modified_time":"2026-02-26T15:20:51+00:00","author":"berta_admin","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"berta_admin","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/#article","isPartOf":{"@id":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/"},"author":{"name":"berta_admin","@id":"https:\/\/iph-multisite.berta-bewegt.ch\/#\/schema\/person\/749c3574947ecc016332eb58d91e45a3"},"headline":"Acc\u00e8s aux nouveaux m\u00e9dicaments, un d\u00e9fi\u00e0 port\u00e9e de main","datePublished":"2025-10-09T11:02:00+00:00","dateModified":"2026-02-26T15:20:51+00:00","mainEntityOfPage":{"@id":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/"},"wordCount":609,"image":{"@id":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/#primaryimage"},"thumbnailUrl":"https:\/\/iph-multisite.berta-bewegt.ch\/wp-content\/uploads\/2026\/02\/width1920quality75formatauto.avif","inLanguage":"fr-FR","copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/iph-multisite.berta-bewegt.ch\/#organization"}},{"@type":"WebPage","@id":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/","url":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/","name":"Acc\u00e8s aux nouveaux m\u00e9dicaments, un d\u00e9fi\u00e0 port\u00e9e de main - Interpharma","isPartOf":{"@id":"https:\/\/iph-multisite.berta-bewegt.ch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/#primaryimage"},"image":{"@id":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/#primaryimage"},"thumbnailUrl":"https:\/\/iph-multisite.berta-bewegt.ch\/wp-content\/uploads\/2026\/02\/width1920quality75formatauto.avif","datePublished":"2025-10-09T11:02:00+00:00","dateModified":"2026-02-26T15:20:51+00:00","author":{"@id":"https:\/\/iph-multisite.berta-bewegt.ch\/#\/schema\/person\/749c3574947ecc016332eb58d91e45a3"},"breadcrumb":{"@id":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/#primaryimage","url":"https:\/\/iph-multisite.berta-bewegt.ch\/wp-content\/uploads\/2026\/02\/width1920quality75formatauto.avif","contentUrl":"https:\/\/iph-multisite.berta-bewegt.ch\/wp-content\/uploads\/2026\/02\/width1920quality75formatauto.avif"},{"@type":"BreadcrumbList","@id":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/blog\/acces-aux-nouveaux-medicaments-un-defia-portee-de-main\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"Acc\u00e8s aux nouveaux m\u00e9dicaments, un d\u00e9fi\u00e0 port\u00e9e de main"}]},{"@type":"WebSite","@id":"https:\/\/iph-multisite.berta-bewegt.ch\/#website","url":"https:\/\/iph-multisite.berta-bewegt.ch\/","name":"Interpharma","description":"Verband der forschenden Pharmazeutischen Firmen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/iph-multisite.berta-bewegt.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/iph-multisite.berta-bewegt.ch\/#\/schema\/person\/749c3574947ecc016332eb58d91e45a3","name":"berta_admin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","caption":"berta_admin"},"sameAs":["https:\/\/iph-multisite.berta-bewegt.ch"]}]}},"_links":{"self":[{"href":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/wp-json\/wp\/v2\/posts\/13874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/wp-json\/wp\/v2\/comments?post=13874"}],"version-history":[{"count":4,"href":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/wp-json\/wp\/v2\/posts\/13874\/revisions"}],"predecessor-version":[{"id":13911,"href":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/wp-json\/wp\/v2\/posts\/13874\/revisions\/13911"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/wp-json\/wp\/v2\/media\/13875"}],"wp:attachment":[{"href":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/wp-json\/wp\/v2\/media?parent=13874"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/iph-multisite.berta-bewegt.ch\/fr\/wp-json\/wp\/v2\/tags?post=13874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}